comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Risk of major adverse events stroke associated treatment with or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis SGLT2 vs GLP-1: Individualizing Diabetes,

A patient with significant constipation, reflux, a history of gallbladder issues, diabetes medication interactions, dehydration risk, or inadequate protein intake may need a different strategy than a patient whose main concern is appetite control

5 Retatrutide and tirzepatide have demonstrated significant improvements in lipid profiles and insulin sensitivity, making them valuable for adolescents at risk for metabolic syndrome

Volume values characterize the mean volume of the circular area centered around the foveola, corresponding to the 6 mm ring of the circular grid defined by the Early Treatment Diabetic Retinopathy Study [23]

Moreover, efpeglenatide therapy reduced the risk of CV disease by about 27% compared to the placebo in the Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O) study [51]

It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases